46.91 +0.01 (0.01%)
After hours: 6:01PM EDT
|Bid||46.30 x 800|
|Ask||47.10 x 1000|
|Day's range||44.62 - 47.22|
|52-week range||12.65 - 54.45|
|PE ratio (TTM)||N/A|
|Earnings date||2 Nov 2017 - 6 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||45.80|
The South San Francisco, California-based company said it had a loss of $1.05 per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Investing success can sometimes be achieved by looking beyond the obvious choices. Check out the growth potential of Shopify, Atara Bio, and Criteo.
On a per-share basis, the South San Francisco, California-based company said it had a loss of $1.15. For the year, the company reported that its loss widened to $119.5 million, or $4 per share. Atara Biotherapeutics ...
Madrigal (MDGL) has no approved product in its portfolio. So, investors' complete focus on fourth-quarter earnings call will be revolving around the company's lead pipeline candidate, MGL-3196.
Of the six analysts covering Atara Biotherapeutics in January 2018, four analysts have given the stock a “buy” or a higher rating, while two analysts have given it a “hold” rating. By comparison, of the 26 analysts covering Amgen (AMGN) in January 2018, 12 analysts have given the company a “buy” or a higher rating, while 14 analysts have given it a “hold” rating. Of the 31 analysts covering Celgene (CELG) in January 2018, 17 analysts have given the stock a “buy” or a higher rating, while 13 analysts have given the stock a “hold” rating, and only one analyst has given it a “sell” rating.
Jim Cramer listed the J.P. Morgan's Healthcare Conference's best and worst performers judging by the stock market's reaction.
Find out how these stocks managed to avoid Friday's minor market slump to end the trading year with a bang.